Barbara Eichhorst, MD, University of Cologne, Cologne, Germany, comments on the efficacy and safety profile of next-generation BTK inhibitors such as acalabrutinib, zanubrutinib, and pirtobrutinib in patients with chronic lymphocytic leukemia (CLL). These BTK inhibitors bind to BTK more specifically and cause therefore fewer side effects. In addition, data has shown that pirtobrutinib is active in patients who are resistant to ibrutinib and acalabrutinib. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Dr Eichhorst receives honoraria for presentations and advisory board from several different pharmaceutical companies involved in targeted agents in CLL (Abbvie, BeiGene, BMS, Gilead, Janssen, MSD, Roche).